Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTERLEUKIN-1 RECEPTOR ANTAGONIST PLASMA-CONCENTRATION IS SPECIFICALLY INCREASED BY INTERFERON-ALPHA-2A TREATMENT
Autore:
NAVEAU S; EMILIE D; BOROTTO E; PORTIER A; LAZIZI Y; GIRAUD V; GRANGEOTKEROS L; CAPRON F; GALANAUD P; CHAPUT JC;
Indirizzi:
HOP ANTOINE BECLERE,SERV HEPATOGASTROENTEROL F-92141 CLAMART FRANCE HOP ANTOINE BECLERE,SERV BACTERIOL IMMUNOL F-92141 CLAMART FRANCE HOP ANTOINE BECLERE,SERV ANAT PATHOL F-92141 CLAMART FRANCE HOP ANTOINE BECLERE,INSERM,U131,INST PARIS SUD CYTOKINES CLAMART FRANCE
Titolo Testata:
Journal of hepatology
fascicolo: 2, volume: 27, anno: 1997,
pagine: 272 - 275
SICI:
0168-8278(1997)27:2<272:IRAPIS>2.0.ZU;2-0
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONIC HEPATITIS-C; INTERFERON-ALPHA; INDUCTION; CYTOKINES; DISEASE; VIRUS; ALFA;
Keywords:
ALPHA-2 INTERFERON; CHRONIC HEPATITIS; INTERLEUKIN-1 RECEPTOR ANTAGONIST;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
14
Recensione:
Indirizzi per estratti:
Citazione:
S. Naveau et al., "INTERLEUKIN-1 RECEPTOR ANTAGONIST PLASMA-CONCENTRATION IS SPECIFICALLY INCREASED BY INTERFERON-ALPHA-2A TREATMENT", Journal of hepatology, 27(2), 1997, pp. 272-275

Abstract

Background/Aims: The mechanism of action of recombinant interferon-alpha (rIFN alpha) treatment in chronic hepatitis C is not fully understood, and may include modulation of the immune system as well as a direct antiviral effect. We have therefore evaluated the plasma concentrations of pro- and anti-inflammatory cytokines in patients with chronic hepatitis C before and during treatment with rIFN alpha. Methods: Twenty-three patients were studied. Plasma concentrations of IL-1 beta, IL-6, TNF, IL-1 receptor antagonist (IL-1RA) and soluble TNF receptors (sTNFRs) type I and type II were determined twice before rIFN alpha treatment (on day -11 and day 1), and on days 11, 32 and 120 of treatment. Results: IL-1 beta, IL-6 and TNF plasma concentrations were rarely increased before treatment (in one, six and seven patients, respectively), and usually declined during treatment, sTNFRs I and II plasma concentrations were not increased either before or during treatment. This was not the case for IL-1RA. In untreated patients, the plasma concentration of IL-1RA was higher than normal in 16 out of 23 patients. WhenrIFN alpha treatment was initiated, there was a constant and dramaticincrease in IL-1RA levels, which reached 8 times the upper limit of the normal range (p<0.001 as compared to pretreatment values). This increase was sustained up to day 120. Conclusions: These results indicatethat induction of an anti-inflammatory status through modulation of the IL-1/IL-1RA balance may be a key mechanism of action of rIFN alpha treatment in chronic hepatitis C.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 20:31:03